New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:34 EDTINCYIncyte duration of response not an issue, says Jefferies
Jefferies says the shorter than expected duration of response for Incyte's '360 with ipilimumab is not an issue since the progression-free survival number is strong. Jefferies believes last night's data suggests that '360 offers up to three times the clinical benefit expected with ipilimumab alone. It maintains a Buy rating on Incyte shares with an $80 price target.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
17:06 EDTINCYIncyte publish Phase III RESPONSE trial results for polycythemia vera patients
Subscribe for More Information
08:10 EDTINCYIncyte receives orphan status for pancreatic cancer treatment
Subscribe for More Information
January 23, 2015
07:36 EDTINCYIncyte earns $25M milestone payment from Novartis for Jakavi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use